Jul 13 2015

Tillis told the National Journal that he has heard from constituents in North Carolina, with its Research Triangle Park interests, and he wants to find a compromise to move the bill forward.

"We have to deal with the patent trolls and a lot of things that are affected in the high-tech sector, but we have our life-science, biotech, pharmaceuticals industry, particularly in North Carolina, and we've got to make sure that we don't create more difficulty in the process " Tillis told the National Journal. "I do think that there are unique considerations for high-tech that are different from considerations for life sciences."

Tillis’ spokeswoman Meghan Burris said by email on Monday:

“Senator Tillis introduced the amendment because it aims to bring predictability, stability and certainty to the pharmaceutical patent process. North Carolina is home to the pharmaceutical and banking industries, small inventor entities, the tech sector and the North Carolina University System, all of which are heavily invested in bringing innovative treatments to patients. It’s simply good policy to provide them with a bit more certainty through the patent process.”

Read full article here.